Carlson Capital L.P. Invests $854,000 in Penumbra, Inc. $PEN

Carlson Capital L.P. purchased a new stake in shares of Penumbra, Inc. (NYSE:PEN – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 2,600 shares of the company’s stock, valued at approximately $854,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Larson Financial Group LLC raised its holdings in Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock valued at $26,000 after buying an additional 82 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Penumbra by 2,700.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock worth $26,000 after acquiring an additional 81 shares in the last quarter. Motiv8 Investments LLC bought a new stake in shares of Penumbra during the 4th quarter worth about $27,000. Morse Asset Management Inc acquired a new position in shares of Penumbra during the 4th quarter valued at about $39,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Penumbra by 27.1% during the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Get Penumbra alerts:

Penumbra Stock Performance

Shares of NYSE PEN opened at $321.40 on Friday. The business has a fifty day simple moving average of $318.75 and a 200 day simple moving average of $330.03. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $12.64 billion, a price-to-earnings ratio of 78.97, a PEG ratio of 1.98 and a beta of 0.70. Penumbra, Inc. has a one year low of $221.26 and a one year high of $362.41.

Penumbra (NYSE:PEN – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a return on equity of 10.70% and a net margin of 10.67%.The business had revenue of $390.05 million for the quarter, compared to analyst estimates of $389.64 million. During the same quarter in the prior year, the firm earned $0.86 EPS. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. Sell-side analysts expect that Penumbra, Inc. will post 5.02 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on PEN shares. Wall Street Zen raised Penumbra to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a report on Friday, July 17th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 price target on shares of Penumbra in a report on Thursday, June 11th. Citigroup reduced their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Penumbra in a report on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Penumbra has an average rating of “Hold” and an average price target of $367.07.

Get Our Latest Analysis on PEN

Penumbra Company Profile

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Further Reading

• Five stocks we like better than Penumbra
• Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
• Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
• Apple’s Record Quarter Could Not Outrun Its Guidance Problem
• McKesson’s Compounding Keeps Adding Up

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.